Association of Mannan Binding Lectin to Liver Fibrosis in Chronic HCV Patients

Wafaa Ezzat

Abstract

The interaction between viral and host immune factors plays an important role in natural history of chronic HCV infection .We aimed to determine serum level of MBL and its relation to grades of liver fibrosis in chronic HCV patients.we studied the impact of serum level of MBL on early virological responsein chronic HCV patients.subjects and methods: included 70 HCV patients (40 HCV patients with liver fibrosis grades <F3 (group Ι) &30 HCV patients with liver. fibrosis ≥F3 (groupΙΙ) according to METAVIR score), who fulfilled inclusion & exclusion criteria of the National Egyptian treatment protocol of treatment of CHC, in addition to 16 control subjects. All studied cases were subjected to history taking, thorough clinical examination, routine investigation(fasting blood sugar, serum creatinine, alkaline phosphatase, ALT, AST, total bilirubin, albumin ,complete blood picture ,prothrombin activity, alpha feto-protein, TSH) ,  abdominal ultrasonography and liver biopsy in addition to ELISA for MBL. Results: mean values of MBL was significantly increased among group 2 patients more than that of group 1(P=0.001). After 12wk of combined therapy, it was found that 61 patients (87.14%) were responders to antiviral therapy, while9 patients (12.85%) were non responders.  The mean value of MBL among responders was 64.44± 26.75 while it was 90.41± 82.41 without any statistically significant differences. So it can be concluded that MBL plays an important role in the pathogenesis of liver fibrosis in HCV liver disease. MBL has no impact on early virological response among patients with chronic HCV infection.

Full Text:

PDF

References

Esmat S, Omran D, Sleem GA and Rashed L (2012): Serum Mannan-Binding Lectin in Egyptian Patients with Chronic Hepatitis C: Its Relation to Disease Progression and Response to Treatment. Hepat Mon.; 12(4):259-64.

EASL Clinical Practice Guidelines(2011): Management of hepatitis C virus infection, European Association for the Study of the Liver, Journal of Hepatology; 55(2):245–264.

Sarrazin C, Berg T and Ross R (2010): Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol; 48(2):289–351.

AlvesPedroso ML, Boldt ABW ,Pereira-Ferrari L ,Steffensen R, Strauss E , Jensenius JC, Ioshii SO , et al.(2008):Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy Journal compilation British Society for Immunology, Clinical and Experimental Immunology;152(2): 258–264.

Tarr AW, Urbanowicz RA and Ball JK (2012): The Role of Humoral Innate Immunity in Hepatitis C Virus Infection. Viruses;4(1):1-27.

Kilpatrick DC, Delahooke TE, Koch C, Turner ML, and Hayes PC(2003):Mannan-binding lectin and hepatitis C infection. ClinExpImmunol; 132(1): 92–95.

Jack DL and Turner MW(2003):Anti-microbial activities of mannose-binding lectin. BiochemSoc Trans; 31(4):753-7.

Franciscus A, 2010: HCV Diagnostic tools: Grading and staging a liver biopsy.HCSP;, Version 2.4.

Koutsounaki E, Goulielmos GN, Koulentaki M, Choulaki C, Kouroumalis E and Galanakis E (2008): Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus infected patients. J ClinImmunol;28(5):495–500.

Ribeiro LZ ,Tripp RA, Rossi LM, Palma PV, Yokosawa J, Mantese OC, et al.(2008): Serum mannose-binding lectin levels are linked with respiratory syncytial virus (RSV) disease. J clinimmunol; 28(2):166-73

ElSaadanySA ,Ziada DH , Farrag W , Hazaa S (2011): .Fibrosis severity and mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex in HCV-infected patients Arab Journal of Gastroenterology; 12(2):68–73.

Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, et al. (2009): Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol. Immunol.;6(4): 235–244.

Heidelbaugh JJ and Bruderly M (2006): Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluation. American Family Physician; 74(5):756-62.

Ytting H, Christensen IJ, Thiel S, Jensenius JC, Svendsen MN, Nielsen L, et al. (2007):Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand J Immunol.;66(4):458-64.

Nadeem A, Hussain M, Aslam M, Hussain T, Butt IF, Ali Khan S, et al.(2009): Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy. J Ayub Med Coll Abbottabad;21(2):103-6.

Derbala M, Al Kaabi S, El Dweik N , Pasic F, Butt MT, Yakoob R, et al. (2006):Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. World J Gastroenterol; 12(35):5692-5698.

Poynard T, McHutchison J, Davis G, Esteban-Mur R, Goodman Z, Bedossa P et al.(2000) :Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology; 32(5):1131–1137.

Manns M, McHutchison J, Gordon S,Rustgi VK, Shiffman M, Reindollar R, et al.(2001): Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet; 358(9286): 958-965.

Dienstag J (2002): The role of liver biopsy in chronic hepatitis C. Hepatology;36(1):152–60.

Bruno S, Shiffman M, Roberts S , Gane EJ, Messinger D, Hadziyannis SJ, et al.(2010): Efficacy and Safety of Peg interferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis. Hepatology; 51(2):388-397.

Refbacks

  • There are currently no refbacks.


Bookmark and Share